NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement

robot
Abstract generation in progress

NewAmsterdam Pharma announced that its Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, under a negotiated separation agreement. This agreement includes a year’s salary, a pro-rated 2026 bonus, payment for unused vacation, and extended equity vesting, showcasing an orderly transition in the company’s senior finance leadership. While the company exhibits solid financial stability with a low-debt balance sheet, it is currently navigating persistent losses and ongoing cash burn.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin